search
Back to results

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Extended Wear infusion set
Standard Infusion set
Heparin
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 12 months
  2. The diagnosis of type 1 diabetes is based on the investigator's judgment; C-peptide level and antibody determinations are not needed.
  3. Age 18 to 55 years
  4. Hemoglobin A1c level less than or equal to 8.5%
  5. Willing to use Novolog insulin while they are participating in the study
  6. Total daily insulin dose is at least 0.3 units/kg/day
  7. For females, not currently known to be pregnant
  8. An understanding of and willingness to follow the protocol and sign the informed consent
  9. Willingness to wear the experimental insulin infusion sets throughout the study
  10. Must be able to understand spoken and written English

Exclusion Criteria:

  1. Diabetic ketoacidosis in the past 3 months
  2. blood urea nitrogen (BUN), Creatinine, or liver function test (ALT or AST) more than three times the upper limit of normal, or thrombocytopenia
  3. Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
  4. Pregnant or lactating females
  5. Known tape allergies
  6. Current treatment for a seizure disorder
  7. Cystic fibrosis
  8. Active infection
  9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
  10. Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
  11. Presence of a known adrenal disorder
  12. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
  13. Abuse of alcohol
  14. Dialysis for renal failure

Sites / Locations

  • Stanford University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Protocol 1: Standard then Extended Set

Protocol 1: Extended then Standard Set

Protocol 2 (Part 1): Sequence 1

Protocol 2 (Part 1): Sequence 2

Protocol 2 (Part 1): Sequence 3

Protocol 2 (Part 1): Sequence 4

Protocol 2 (Part 1): Sequence 5

Protocol 2 (Part 2): Standard then Extended Set

Protocol 2 (Part 1): Extended then Standard Set

Arm Description

Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.

Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.

Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).

Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).

Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).

Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).

Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).

Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.

Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.

Outcomes

Primary Outcome Measures

Time to an infusion set failure due to an occlusion
Glucose >250 mg/dL with failure of a correction dose to lower the glucose by 50 mg/dL, or ketones > or = 0.6 mg/dL with a glucose reading of >250 mg/dL (in the absence of illness), or a pump occlusion alarm

Secondary Outcome Measures

signs of infection at insulin infusion site
erythema or induration of > 1cm in diameter at injection site

Full Information

First Posted
February 9, 2016
Last Updated
June 1, 2018
Sponsor
Stanford University
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT02687256
Brief Title
Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set
Official Title
Evaluation of Extended Infusion Set Wear Using the Medtronic Extended Wear Sof-set Infusion Set
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
Collaborators
Medtronic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a blinded cross-over study to see if extended wear insulin infusion sets can prolong insulin infusion set wear up to 7 days in adults with Type 1 Diabetes.
Detailed Description
This is a double blinded cross-over study. Subjects will be asked to wear infusion set either a standard infusion set or an extended wear infusion set. They will wear each infusion set twice, and the order of infusion set wear will be randomized with the first infusion set wear and then alternated over 4 weeks. By performing a cross over study using both experimental infusion sets and standard infusion sets, the investigators hope to see whether there is a benefit to using an extended wear infusion set.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Protocol 1: Standard then Extended Set
Arm Type
Experimental
Arm Description
Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
Arm Title
Protocol 1: Extended then Standard Set
Arm Type
Experimental
Arm Description
Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
Arm Title
Protocol 2 (Part 1): Sequence 1
Arm Type
Experimental
Arm Description
Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
Arm Title
Protocol 2 (Part 1): Sequence 2
Arm Type
Experimental
Arm Description
Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
Arm Title
Protocol 2 (Part 1): Sequence 3
Arm Type
Experimental
Arm Description
Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
Arm Title
Protocol 2 (Part 1): Sequence 4
Arm Type
Experimental
Arm Description
Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
Arm Title
Protocol 2 (Part 1): Sequence 5
Arm Type
Experimental
Arm Description
Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
Arm Title
Protocol 2 (Part 2): Standard then Extended Set
Arm Type
Experimental
Arm Description
Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
Arm Title
Protocol 2 (Part 1): Extended then Standard Set
Arm Type
Experimental
Arm Description
Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
Intervention Type
Device
Intervention Name(s)
Extended Wear infusion set
Intervention Description
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
Intervention Type
Device
Intervention Name(s)
Standard Infusion set
Other Intervention Name(s)
Minimed
Intervention Description
For two of the 4 weeks the Standard infusion set will be used
Intervention Type
Drug
Intervention Name(s)
Heparin
Primary Outcome Measure Information:
Title
Time to an infusion set failure due to an occlusion
Description
Glucose >250 mg/dL with failure of a correction dose to lower the glucose by 50 mg/dL, or ketones > or = 0.6 mg/dL with a glucose reading of >250 mg/dL (in the absence of illness), or a pump occlusion alarm
Time Frame
within 1 week
Secondary Outcome Measure Information:
Title
signs of infection at insulin infusion site
Description
erythema or induration of > 1cm in diameter at injection site
Time Frame
1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 12 months The diagnosis of type 1 diabetes is based on the investigator's judgment; C-peptide level and antibody determinations are not needed. Age 18 to 55 years Hemoglobin A1c level less than or equal to 8.5% Willing to use Novolog insulin while they are participating in the study Total daily insulin dose is at least 0.3 units/kg/day For females, not currently known to be pregnant An understanding of and willingness to follow the protocol and sign the informed consent Willingness to wear the experimental insulin infusion sets throughout the study Must be able to understand spoken and written English Exclusion Criteria: Diabetic ketoacidosis in the past 3 months blood urea nitrogen (BUN), Creatinine, or liver function test (ALT or AST) more than three times the upper limit of normal, or thrombocytopenia Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment Pregnant or lactating females Known tape allergies Current treatment for a seizure disorder Cystic fibrosis Active infection A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian) Presence of a known adrenal disorder If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study Abuse of alcohol Dialysis for renal failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce Buckingham, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
To maintain the integrity of this research study, the subject is told they may not have access to any health information developed as part of this study until it is completed.

Learn more about this trial

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

We'll reach out to this number within 24 hrs